Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Sustainability
The Rise of ESG: Where It Is Now and How It Got Here
Calls for corporate reform are as old as the corporation itself, so why now are companies pushing for more ESG efforts in their organizations?
By
Ted Jackson
| July 5, 2022
Read More
Resources
CFO Live
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
Sign Up
Sponsored by
Pharmaceutical industry
Risk & Compliance
Mylan Underpaid U.S. on Rebates for EpiPen
A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
By
Matthew Heller
| October 6, 2016
Read More
Strategy
Merck Buys Cough Drug Developer for $1.25B
The acquisition of Afferent Pharmaceuticals gives Merck access to a drug candidate for treating neurogenic conditions including chronic cough.
By
Katie Kuehner-Hebert
| June 10, 2016
Read More
Strategy
Pfizer Adds Eczema Gel With $5B Anacor Deal
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
By
Katie Kuehner-Hebert
| May 16, 2016
Read More
Risk & Compliance
Biotech CFO Accused of Misleading Investors
The ex-CFO of Aveo Pharmaceuticals and other top executives allegedly failed to disclose FDA concerns about an experimental cancer drug.
By
Matthew Heller
| March 30, 2016
Read More
Strategy
Ireland’s Shire Buys Baxalta for $32 Billion
The drug maker says the deal will further its goal of "building the leading biotechnology company focused on rare diseases."
By
Katie Kuehner-Hebert
| January 11, 2016
Read More
People
Valeant Stock Falls 10% on News of CEO’s Illness
Michael Pearson, who was hospitalized with pneumonia, has been trying to win back investor trust amid concerns over Valeant's pricing practices.
By
Katie Kuehner-Hebert
| December 28, 2015
Read More
Risk & Compliance
Novartis Settles Kickback Charges for $370M
The Swiss drug maker allegedly turned specialty pharmacies into a "biased sales force" for its medications.
By
Matthew Heller
| November 20, 2015
Read More
Strategy
Shire to Buy Rival Drug Maker Dyax for $5.9B
The deal gives the acquisitive Irish company access to an experimental drug that competes with its own treatment for a rare disease.
By
Matthew Heller
| November 2, 2015
Read More
Strategy
Cipla Buys Two U.S. Pharma Firms for $550M
The acquisitions give the Indian drug maker its first manufacturing plant in the U.S. and an opportunity to build U.S. market share.
By
Katie Kuehner-Hebert
| September 4, 2015
Read More
Strategy
Teva to Buy Allergan’s Generic Drug Unit for $40.5B
If the deal is approved, Teva says the combined company would have revenue of about $26 billion and EBITDA of $9.5 billion in 2016.
By
Katie Kuehner-Hebert
| July 27, 2015
Read More